NORTH CHICAGO, Ill., Dec. 12, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and safety results from MURANO, an international, multicenter, open-label, randomized Phase 3 study…